Compare KVUE & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVUE | ALC |
|---|---|---|
| Founded | 2022 | 1945 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9B | 34.1B |
| IPO Year | 2023 | 2002 |
| Metric | KVUE | ALC |
|---|---|---|
| Price | $17.81 | $66.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $19.45 | ★ $89.38 |
| AVG Volume (30 Days) | ★ 18.3M | 1.3M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.82% | 0.25% |
| EPS Growth | ★ 40.74 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $15,124,000,000.00 | N/A |
| Revenue This Year | $4.85 | $7.99 |
| Revenue Next Year | $2.63 | $6.38 |
| P/E Ratio | ★ $36.98 | $38.31 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.02 | $61.84 |
| 52 Week High | $20.13 | $87.64 |
| Indicator | KVUE | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 31.89 | 30.74 |
| Support Level | $16.78 | $66.08 |
| Resistance Level | $19.15 | $68.25 |
| Average True Range (ATR) | 0.31 | 1.01 |
| MACD | -0.15 | -0.78 |
| Stochastic Oscillator | 6.61 | 1.11 |
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.